{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T19:56:23Z","timestamp":1717790183002},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Most non-Hodgkin's lymphomas (NHL) initially respond to chemotherapy, but relapse is common and treatment is often limited by chemotherapy-related toxicity. Bortezomib, is a highly selective proteasome inhibitor with anti-NHL activity; it is currently FDA approved for second-line treatment of mantle cell lymphoma (MCL). Bortezomib exerts its activity in part through the generation of reactive oxygen species (ROS) and also by the induction of apoptosis.<\/jats:p><jats:p>We previously validated CD22 as a potential target in treating NHL and have shown that the anti-CD22 ligand blocking antibody, HB22.7, has significant independent lymphomacidal properties in NHL xenograft models. We sought to determine whether or not these agents would work synergistically to enhance cytotoxicity. Our results indicate that treatment of NHL cell lines with HB22.7 six hours prior to bortezomib significantly diminished cell viability. These effects were not seen when the agents were administered alone or when bortezomib was administered prior to HB22.7. Additionally, HB22.7 treatment prior to bortezomib increased apoptosis in part through enhanced ROS generation. Finally, in a mouse xenograft model, administration of HB22.7 followed 24 hours later by bortezomib resulted in 23% smaller tumor volumes and 20% enhanced survival compared to treatment with the reverse sequence. Despite the increased efficacy of HB22.7 treatment followed by bortezomib, there was no corresponding decrease in peripheral blood cell counts, indicating no increase in toxicity. Our results suggest that pre-treatment with HB22.7 increases bortezomib cytotoxicity, in part through increased reactive oxygen species and apoptosis, and that this sequential treatment combination has robust efficacy<jats:italic>in vivo<\/jats:italic>.<\/jats:p>","DOI":"10.1186\/1756-8722-4-49","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T14:13:12Z","timestamp":1322835192000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner"],"prefix":"10.1186","volume":"4","author":[{"given":"Shiloh M","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayes","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunpeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M","family":"Tuscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,1]]},"reference":[{"key":"188_CR1","first-page":"46","volume-title":"Progress in Oncology","author":"ST Schumer","year":"2003","unstructured":"Schumer ST, Joyce RM: Radioimmunotherapy for Non-Hodgkin's Lymphoma. Progress in Oncology. 2003, 46-72."},{"key":"188_CR2","volume-title":"SEER Cancer Statistics Review, 1975-2005","author":"L Ries","year":"2008","unstructured":"Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, Mariotto A, Miller B, Feuer E, Altekruse S, Lewis D, Clegg L, Eisner M, Reichman M, Edwards Be: SEER Cancer Statistics Review, 1975-2005. 2008, National Cancer Institute, Bethesda, MD"},{"key":"188_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev.pharmtox.46.120604.141300","volume":"46","author":"PM Voorhees","year":"2006","unstructured":"Voorhees PM, Orlowski RZ: The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 2006, 46: 189-213. 10.1146\/annurev.pharmtox.46.120604.141300.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"188_CR4","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61: 3071-3076.","journal-title":"Cancer Res"},{"key":"188_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P Perez-Galan","year":"2006","unstructured":"Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D: The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006, 107: 257-264. 10.1182\/blood-2005-05-2091.","journal-title":"Blood"},{"key":"188_CR6","doi-asserted-by":"publisher","first-page":"9695","DOI":"10.1128\/MCB.24.22.9695-9704.2004","volume":"24","author":"A Fribley","year":"2004","unstructured":"Fribley A, Zeng Q, Wang CY: Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004, 24: 9695-9704. 10.1128\/MCB.24.22.9695-9704.2004.","journal-title":"Mol Cell Biol"},{"key":"188_CR7","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Lee KP, Boise LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006, 107: 4907-4916. 10.1182\/blood-2005-08-3531.","journal-title":"Blood"},{"key":"188_CR8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1080\/10428190902895780","volume":"50","author":"H Dong","year":"2009","unstructured":"Dong H, Chen L, Chen X, Gu H, Gao G, Gao Y, Dong B: Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk Lymphoma. 2009, 50: 974-984. 10.1080\/10428190902895780.","journal-title":"Leuk Lymphoma"},{"key":"188_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","volume":"171","author":"LV Pham","year":"2003","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ: Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003, 171: 88-95.","journal-title":"J Immunol"},{"key":"188_CR10","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/nm.1864","volume":"14","author":"DX Fu","year":"2008","unstructured":"Fu DX, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong JM, Hobbs RF, Fukayama M, Sgouros G, Kowalski J, Pomper MG, Ambinder RF: Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med. 2008, 14: 1118-1122. 10.1038\/nm.1864.","journal-title":"Nat Med"},{"key":"188_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005, 23: 667-675. 10.1200\/JCO.2005.03.108.","journal-title":"J Clin Oncol"},{"key":"188_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdl316","volume":"18","author":"A Belch","year":"2007","unstructured":"Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, Powers J, Wright J, Eisenhauer EA: A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol. 2007, 18: 116-121.","journal-title":"Ann Oncol"},{"key":"188_CR13","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006, 24: 4867-4874. 10.1200\/JCO.2006.07.9665.","journal-title":"J Clin Oncol"},{"key":"188_CR14","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA: Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006, 24: 2105-2112. 10.1200\/JCO.2005.04.6789.","journal-title":"J Clin Oncol"},{"key":"188_CR15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O'Connor","year":"2005","unstructured":"O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005, 23: 676-684. 10.1200\/JCO.2005.02.050.","journal-title":"J Clin Oncol"},{"key":"188_CR16","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","volume":"27","author":"S de Vos","year":"2009","unstructured":"de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL: Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009, 27: 5023-5030. 10.1200\/JCO.2008.17.7980.","journal-title":"J Clin Oncol"},{"key":"188_CR17","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1182\/blood.V87.11.4723.bloodjournal87114723","volume":"87","author":"J Tuscano","year":"1996","unstructured":"Tuscano J, Engel P, Tedder TF, Kehrl JH: Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22\/CD22L interactions impairs T-cell proliferation. Blood. 1996, 87: 4723-4730.","journal-title":"Blood"},{"key":"188_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.immunol.15.1.481","volume":"15","author":"TF Tedder","year":"1997","unstructured":"Tedder TF, Tuscano J, Sato S, Kehrl JH: CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997, 15: 481-504. 10.1146\/annurev.immunol.15.1.481.","journal-title":"Annu Rev Immunol"},{"key":"188_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1006\/smim.1998.0121","volume":"10","author":"S Sato","year":"1998","unstructured":"Sato S, Tuscano JM, Inaoki M, Tedder TF: CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol. 1998, 10: 287-297. 10.1006\/smim.1998.0121.","journal-title":"Semin Immunol"},{"key":"188_CR20","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V94.4.1382","volume":"94","author":"JM Tuscano","year":"1999","unstructured":"Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH: CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK\/SAPK signaling cascade. Blood. 1999, 94: 1382-1392.","journal-title":"Blood"},{"key":"188_CR21","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.4049\/jimmunol.177.5.3063","volume":"177","author":"KM Haas","year":"2006","unstructured":"Haas KM, Sen S, Sanford IG, Miller AS, Poe JC, Tedder TF: CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol. 2006, 177: 3063-3073.","journal-title":"J Immunol"},{"key":"188_CR22","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1182\/blood-2002-08-2629","volume":"101","author":"JM Tuscano","year":"2003","unstructured":"Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL: Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood. 2003, 101: 3641-3647. 10.1182\/blood-2002-08-2629.","journal-title":"Blood"},{"key":"188_CR23","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1158\/1078-0432.CCR-08-2365","volume":"15","author":"S Bhalla","year":"2009","unstructured":"Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM: PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 2009, 15: 3354-3365. 10.1158\/1078-0432.CCR-08-2365.","journal-title":"Clin Cancer Res"},{"key":"188_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.leu.2404471","volume":"21","author":"T Haritunians","year":"2007","unstructured":"Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP: Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia. 2007, 21: 333-339. 10.1038\/sj.leu.2404471.","journal-title":"Leukemia"},{"key":"188_CR25","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.leukres.2006.03.005","volume":"30","author":"P Smolewski","year":"2006","unstructured":"Smolewski P, Duechler M, Linke A, Cebula B, Grzybowska-Izydorczyk O, Shehata M, Robak T: Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leuk Res. 2006, 30: 1521-1529. 10.1016\/j.leukres.2006.03.005.","journal-title":"Leuk Res"},{"key":"188_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/sj.leu.2404959","volume":"22","author":"M Wang","year":"2008","unstructured":"Wang M, Han XH, Zhang L, Yang J, Qian JF, Shi YK, Kwak LW, Romaguera J, Yi Q: Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008, 22: 179-185. 10.1038\/sj.leu.2404959.","journal-title":"Leukemia"},{"key":"188_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4161\/mabs.1.1.7472","volume":"1","author":"L Alinari","year":"2009","unstructured":"Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA: Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs. 2009, 1: 31-40. 10.4161\/mabs.1.1.7472.","journal-title":"MAbs"},{"key":"188_CR28","first-page":"1183","volume":"2","author":"AR Jazirehi","year":"2003","unstructured":"Jazirehi AR, Gan XH, De Vos S, Emmanouilides C, Bonavida B: Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2003, 2: 1183-1193.","journal-title":"Mol Cancer Ther"},{"key":"188_CR29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","volume":"65","author":"AR Jazirehi","year":"2005","unstructured":"Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B: Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 2005, 65: 264-276.","journal-title":"Cancer Res"},{"key":"188_CR30","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1128\/MCB.19.4.2690","volume":"19","author":"M Hinz","year":"1999","unstructured":"Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M: NF-kappaB function in growth control: regulation of cyclin D1 expression and G0\/G1-to-S-phase transition. Mol Cell Biol. 1999, 19: 2690-2698.","journal-title":"Mol Cell Biol"},{"key":"188_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1046\/j.1365-2141.2003.04438.x","volume":"122","author":"C Bogner","year":"2003","unstructured":"Bogner C, Ringshausen I, Schneller F, Fend F, Quintanilla-Martinez L, Hacker G, Goetze K, Oostendorp R, Peschel C, Decker T: Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. Br J Haematol. 2003, 122: 260-268. 10.1046\/j.1365-2141.2003.04438.x.","journal-title":"Br J Haematol"},{"key":"188_CR32","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood.V98.9.2771","volume":"98","author":"B Bellosillo","year":"2001","unstructured":"Bellosillo B, Villamor N, Lopez-Guillermo A, Marce S, Esteve J, Campo E, Colomer D, Montserrat E: Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001, 98: 2771-2777. 10.1182\/blood.V98.9.2771.","journal-title":"Blood"},{"key":"188_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1054\/drup.2000.0165","volume":"3","author":"MA Shah","year":"2000","unstructured":"Shah MA, Schwartz GK: The relevance of drug sequence in combination chemotherapy. Drug Resist Updat. 2000, 3: 335-356. 10.1054\/drup.2000.0165.","journal-title":"Drug Resist Updat"},{"key":"188_CR34","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/S0959-8049(01)00309-4","volume":"37","author":"CH Smorenburg","year":"2001","unstructured":"Smorenburg CH, Sparreboom A, Bontenbal M, Verweij J: Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur J Cancer. 2001, 37: 2310-2323. 10.1016\/S0959-8049(01)00309-4.","journal-title":"Eur J Cancer"},{"key":"188_CR35","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<729::AID-IJC20>3.0.CO;2-#","volume":"73","author":"S Guichard","year":"1997","unstructured":"Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P: Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer. 1997, 73: 729-734. 10.1002\/(SICI)1097-0215(19971127)73:5<729::AID-IJC20>3.0.CO;2-#.","journal-title":"Int J Cancer"},{"key":"188_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00280-007-0609-2","volume":"62","author":"N Aissat","year":"2008","unstructured":"Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S: Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol. 2008, 62: 305-313. 10.1007\/s00280-007-0609-2.","journal-title":"Cancer Chemother Pharmacol"},{"key":"188_CR37","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/j.1349-7006.1998.tb00532.x","volume":"89","author":"S Fujimoto","year":"1998","unstructured":"Fujimoto S, Chikazawa H: Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo. Jpn J Cancer Res. 1998, 89: 1343-1351. 10.1111\/j.1349-7006.1998.tb00532.x.","journal-title":"Jpn J Cancer Res"},{"key":"188_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/07357909309020256","volume":"11","author":"AL Adel","year":"1993","unstructured":"Adel AL, Dorr RT, Liddil JD: The effect of anticancer drug sequence in experimental combination chemotherapy. Cancer Invest. 1993, 11: 15-24. 10.3109\/07357909309020256.","journal-title":"Cancer Invest"},{"key":"188_CR39","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/sj.leu.2404528","volume":"21","author":"P Bonvini","year":"2007","unstructured":"Bonvini P, Zorzi E, Basso G, Rosolen A: Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia. 2007, 21: 838-842.","journal-title":"Leukemia"},{"key":"188_CR40","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1158\/1078-0432.CCR-03-0494","volume":"10","author":"B Zheng","year":"2004","unstructured":"Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, Younes A: Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res. 2004, 10: 3207-3215. 10.1158\/1078-0432.CCR-03-0494.","journal-title":"Clin Cancer Res"},{"key":"188_CR41","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1182\/blood-2004-10-3984","volume":"105","author":"A Nencioni","year":"2005","unstructured":"Nencioni A, Hua F, Dillon CP, Yokoo R, Scheiermann C, Cardone MH, Barbieri E, Rocco I, Garuti A, Wesselborg S, Belka C, Brossart P, Patrone F, Ballestrero A: Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood. 2005, 105: 3255-3262. 10.1182\/blood-2004-10-3984.","journal-title":"Blood"},{"key":"188_CR42","doi-asserted-by":"publisher","first-page":"7863","DOI":"10.1038\/sj.onc.1208069","volume":"23","author":"M Herrant","year":"2004","unstructured":"Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F, Auberger P: Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene. 2004, 23: 7863-7873. 10.1038\/sj.onc.1208069.","journal-title":"Oncogene"},{"key":"188_CR43","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.4049\/jimmunol.154.7.3096","volume":"154","author":"N Chaouchi","year":"1995","unstructured":"Chaouchi N, Vazquez A, Galanaud P, Leprince C: B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking. J Immunol. 1995, 154: 3096-3104.","journal-title":"J Immunol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-4-49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T11:02:53Z","timestamp":1686481373000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-4-49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["188"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-4-49","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"1 November 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"49"}}